SG10201911225WA - Methods of treating neurodegenerative diseases - Google Patents
Methods of treating neurodegenerative diseasesInfo
- Publication number
- SG10201911225WA SG10201911225WA SG10201911225WA SG10201911225WA SG10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA SG 10201911225W A SG10201911225W A SG 10201911225WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- neurodegenerative diseases
- treating neurodegenerative
- treating
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477535P | 2017-03-28 | 2017-03-28 | |
| US201762532696P | 2017-07-14 | 2017-07-14 | |
| US201762577559P | 2017-10-26 | 2017-10-26 | |
| US201762580359P | 2017-11-01 | 2017-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911225WA true SG10201911225WA (en) | 2020-01-30 |
Family
ID=62063590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911225WA SG10201911225WA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
| SG11201908326Y SG11201908326YA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908326Y SG11201908326YA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200131255A1 (en) |
| EP (1) | EP3601337A1 (en) |
| JP (2) | JP2020515543A (en) |
| KR (1) | KR20190133162A (en) |
| CN (2) | CN110494446A (en) |
| AU (1) | AU2018244224A1 (en) |
| CA (1) | CA3055758A1 (en) |
| IL (1) | IL269106A (en) |
| MA (1) | MA48996A (en) |
| MX (1) | MX2019011423A (en) |
| SG (2) | SG10201911225WA (en) |
| TW (2) | TW202400231A (en) |
| WO (1) | WO2018183175A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6674888B2 (en) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | Tau immunotherapy |
| CA2986942A1 (en) | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| KR102471787B1 (en) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | Tau recognition antibody |
| PT3452507T (en) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Tau immunotherapy |
| CN110248959B (en) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | anti-TAU antibodies and methods of use |
| AU2017373889A1 (en) | 2016-12-07 | 2019-06-06 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| CN110520440A (en) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | Anti- τ antibody and its application method |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| TW202328177A (en) * | 2021-08-27 | 2023-07-16 | 美商建南德克公司 | Methods of treating tau pathologies |
| WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| JP3951062B2 (en) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| DE122004000036I1 (en) | 1992-11-13 | 2005-07-07 | Biogen Idec Inc | Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma. |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ATE419009T1 (en) | 1997-10-31 | 2009-01-15 | Genentech Inc | METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS |
| BR9813365A (en) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (en) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CN1763097B (en) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | Polypeptide variants with altered effector function |
| ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| PT1222292E (en) | 1999-10-04 | 2005-11-30 | Medicago Inc | METHOD FOR REGULATING THE TRANSCRIPTION OF EXOGENEOUS GENES IN THE PRESENCE OF NITROGEN |
| WO2001029246A1 (en) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| BR0110610A (en) | 2000-04-11 | 2003-04-29 | Genentech Inc | Isolated antibodies, immunoconjugates, polypeptide chains, isolated nucleic acid, vector, host cell, antibody or polypeptide chain production process, method of treating mammalian dysfunction, method of inducing apoptosis of a cancer cell, method of killing a cell b, method for killing a cell expressing an erbb receptor and uses of isolated antibodies |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2620359T3 (en) | 2000-10-06 | 2017-06-28 | Kyowa Hakko Kirin Co., Ltd. | Cells that produce antibody compositions |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| KR20100018071A (en) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1500698B1 (en) | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
| JPWO2003084569A1 (en) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | Antibody composition-containing medicine |
| EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| JPWO2003085118A1 (en) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | Method for producing antibody composition |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| BRPI0316779B8 (en) | 2002-12-16 | 2023-02-28 | Genentech Inc | HUMAN ANTI-CD20 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, ITS USES, COMPOSITION, MANUFACTURED ARTICLE AND LIQUID FORMULATION |
| US20060135403A1 (en) | 2002-12-24 | 2006-06-22 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| JPWO2005035778A1 (en) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | Method for producing antibody composition using RNA that suppresses function of α1,6-fucosyltransferase |
| ME01775B (en) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
| JPWO2005053742A1 (en) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | Medicament containing antibody composition |
| US7527791B2 (en) | 2004-03-31 | 2009-05-05 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
| BR122019012028B1 (en) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | ANTI-P-SELECTIN ANTIBODIES, NUCLEIC ACID MOLECULE, VECTOR, AND COMPOSITION |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP3088004B1 (en) | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CA2813493C (en) | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| BR112015003326A2 (en) | 2012-08-16 | 2017-07-04 | Ipierian Inc | methods of treatment of a tauopathy |
| KR102234324B1 (en) | 2012-12-21 | 2021-03-31 | 바이오젠 엠에이 인코포레이티드 | Human anti-tau antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP6674888B2 (en) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | Tau immunotherapy |
| TW202136296A (en) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| CA2986942A1 (en) * | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
-
2018
- 2018-03-26 SG SG10201911225WA patent/SG10201911225WA/en unknown
- 2018-03-26 KR KR1020197026447A patent/KR20190133162A/en not_active Application Discontinuation
- 2018-03-26 EP EP18720677.6A patent/EP3601337A1/en active Pending
- 2018-03-26 TW TW112109248A patent/TW202400231A/en unknown
- 2018-03-26 MA MA048996A patent/MA48996A/en unknown
- 2018-03-26 CN CN201880021209.2A patent/CN110494446A/en active Pending
- 2018-03-26 TW TW107110248A patent/TW201836640A/en unknown
- 2018-03-26 WO PCT/US2018/024300 patent/WO2018183175A1/en unknown
- 2018-03-26 MX MX2019011423A patent/MX2019011423A/en unknown
- 2018-03-26 CN CN202311141590.5A patent/CN117205311A/en active Pending
- 2018-03-26 SG SG11201908326Y patent/SG11201908326YA/en unknown
- 2018-03-26 JP JP2019552543A patent/JP2020515543A/en active Pending
- 2018-03-26 AU AU2018244224A patent/AU2018244224A1/en active Pending
- 2018-03-26 CA CA3055758A patent/CA3055758A1/en active Pending
-
2019
- 2019-09-03 IL IL26910619A patent/IL269106A/en unknown
- 2019-09-19 US US16/576,249 patent/US20200131255A1/en not_active Abandoned
-
2021
- 2021-01-15 US US17/150,201 patent/US20210284720A1/en active Pending
-
2023
- 2023-01-12 JP JP2023002900A patent/JP2023055720A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201836640A (en) | 2018-10-16 |
| AU2018244224A1 (en) | 2019-09-19 |
| IL269106A (en) | 2019-11-28 |
| JP2023055720A (en) | 2023-04-18 |
| RU2019130976A (en) | 2021-04-28 |
| CN110494446A (en) | 2019-11-22 |
| SG11201908326YA (en) | 2019-10-30 |
| EP3601337A1 (en) | 2020-02-05 |
| KR20190133162A (en) | 2019-12-02 |
| CN117205311A (en) | 2023-12-12 |
| US20210284720A1 (en) | 2021-09-16 |
| MX2019011423A (en) | 2019-11-01 |
| CA3055758A1 (en) | 2018-10-04 |
| TW202400231A (en) | 2024-01-01 |
| WO2018183175A1 (en) | 2018-10-04 |
| MA48996A (en) | 2020-02-05 |
| US20200131255A1 (en) | 2020-04-30 |
| RU2019130976A3 (en) | 2021-09-13 |
| JP2020515543A (en) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| IL269106A (en) | Methods of treating neurodegenerative diseases | |
| HK1245078A1 (en) | Methods of treating a neurodegenerative disease | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| IL253118A0 (en) | Methods of treating inflammatory diseases | |
| HK1252037A1 (en) | Methods of treating inflammatory diseases | |
| ZA201903873B (en) | Methods of treating cochlear synaptopathy | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| HK1258994A1 (en) | Methods for treatment of diseases | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| HK1247818A1 (en) | Method of treating diseases | |
| GB201706406D0 (en) | Method of treatment | |
| GB201815588D0 (en) | Method of treatment | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
| GB201602802D0 (en) | Method of treatment | |
| HK1243937A1 (en) | Methods of treating diseases | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| EP3426280A4 (en) | Methods of treating neurodegenerative diseases | |
| GB201714316D0 (en) | Treatement of neurodegenerative diseases | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| GB201720439D0 (en) | Method of treatment |